“Alzheimer’s disease researchers were buoyed by positive data released Tuesday from a large clinical trial of an experimental therapy being developed by Biogen and Eisai. The early data suggest that the treatment, called lecanemab, eases cognitive decline. The...
“The news: University of Washington spinout AltPep recently raised $44.4 million, according to a regulatory filing. The company declined to discuss the filing, but founder and CEO Valerie Daggett spoke with GeekWire about AltPep’s progress on its experimental...
Review Full Article and Download as a PDF. By Dylan Shea and Valerie Daggett. Biophysica 2022, 2(2), 91-110; https://doi.org/10.3390/biophysica2020010 Received: 7 April 2022 / Revised: 27 April 2022 / Accepted: 27 April 2022 / Published: 28 April 2022...
Breakthrough designation reinforces the significant potential of SOBA-AD assay to address the unmet need in Alzheimer’s Disease (AD) detection SOBA-AD assay is designed to selectively detect toxic oligomers that trigger a cascade of events associated with AD,...
SEATTLE, WA – AltPep Corporation, a privately held biotechnology company developing early disease-modifying treatments and detection tools for amyloid diseases, today announced that accomplished executive Nancy Hill has assumed the newly created role of Chief Product...
Join UW Vice Provost for Innovation & CoMotion Director François Baneyx as he speaks with Dr. Valerie Daggett, Founder & CEO of UW spinoff AltPep (https://www.altpep.com/) and professor of bioengineering at the University of Washington, about her...
AltPep announces closing $23.150 million Series A investment round, let by Matrix Capital Management with significant participation by Alexandria Venture Investments. In conjunction with the financing, David Goel, Managing General Partner and Co-founder of Matrix...
Recent Comments